Tengonermin
Tengonermin (ARENEGYR) is a vascular-targeting agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. Tengonermin increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment[1][2].
Product Specifications
CAS Number
1960461-99-7
Product Name Alternative
ARENEGYR; NGR-TNF; NGR-hTNF
UNSPSC
12352203
Target
TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tengonermin.html
Solubility
H2O
Smiles
[Tengonermin]
References & Citations
[1]Valentinis B, et, al. Mechanism of Action of the Tumor Vessel Targeting Agent NGR-hTNF: Role of Both NGR Peptide and hTNF in Cell Binding and Signaling. Int J Mol Sci. 2019 Sep 12;20 (18) :4511. |[2]Gregorc V, et, al. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015) : a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2018 Jun;19 (6) :799-811.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
PKSV030268 100 µg
Recombinant ZIKV (strain Zika SPH2015) Membrane protein (Fc Tag)
Sign In for Pricing
View Details 